Clearmind Medicine (CMND) Change in Account Payables (2022 - 2026)
Clearmind Medicine (CMND) posted quarterly Change in Account Payables of -$99546.0 for Q2 2026, down 95.56% year-over-year from -$2.2 million in Q2 2025, and down 172.92% quarter-over-quarter from $136517.0 in Q1 2026.
Clearmind Medicine (CMND) Change in Account Payables (2022 - 2026) Analysis & Trends
Clearmind Medicine's Change in Account Payables history runs 5 years deep, the most recent figure standing at -$99546.0 for Q2 2026.
- In Q2 2026, Change in Account Payables fell 95.56% year-over-year to -$99546.0; the TTM figure through Apr 2026 stood at $171728.0 (up 167.14% YoY), while the FY2025 annual figure was $82788.0, up 141.69% from the prior year.
- Change in Account Payables for Q2 2026 stood at -$99546.0, down from $136517.0 in the prior quarter.
- The five-year high for Change in Account Payables was $181.6 billion in Q3 2022, with the low at -$181.6 billion in Q4 2022.
- The 5-year median for Change in Account Payables is -$6730.0 (2023), against an average of $13256.5.
- The sharpest annual moves came in 2024 and 2026: Change in Account Payables tumbled 5657.5% in 2024, then surged 12918.5% in 2026.
- Clearmind Medicine's Change in Account Payables stood at -$181.6 billion in 2022, then surged by 100.0% to -$455518.0 in 2023, then surged by 140.32% to $183685.0 in 2024, then tumbled by 80.93% to $35032.0 in 2025, then slumped by 384.16% to -$99546.0 in 2026.
- Business Quant data shows CMND's Change in Account Payables at -$99546.0 in Q2 2026, $136517.0 in Q1 2026, and $35032.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | -196,057.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -99,546.00 |
| Apr 30, 2026 | -99,546.00 |
| Jan 31, 2026 | 136,517.00 |
| Jan 31, 2026 | 136,517.00 |
| Oct 31, 2025 | 35,032.00 |
| Oct 31, 2025 | 35,032.00 |
| Jul 31, 2025 | 99,725.00 |
| Jul 31, 2025 | 99,725.00 |
| Apr 30, 2025 | -50,904.00 |
| Apr 30, 2025 | -50,904.00 |
| Jan 31, 2025 | -1,065.00 |
| Jan 31, 2025 | -1,065.00 |
| Oct 31, 2024 | 183,685.00 |
| Oct 31, 2024 | 183,685.00 |
| Jul 31, 2024 | -387,480.00 |
| Jul 31, 2024 | -387,480.00 |
| Apr 30, 2024 | 227,562.00 |
| Apr 30, 2024 | 227,562.00 |
| Jan 31, 2024 | -222,357.00 |
| Jan 31, 2024 | -222,357.00 |